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with increased risk of mortality and myocardial infarction after cor-
onary intervention. Beneﬁcial effect of clopidogrel may be attenuated
by drug interaction with PPI.
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BACKGROUND Recently, ACEF (age, creatinine, ejection fraction)
score showed prognostic value predicting major adverse cardiac
events (MACEs) in patients undergoing percutaneous coronary inter-
vention (PCI) after acute myocardial infarction (AMI). However, it has
not been fully validated yet in large population. We aimed to assess
whether ACEF score would improve the ability of the GRACE score to
predict MACEs of patients undergoing PCI after AMI.
METHODS Between November 2005 and July 2014, 11,549 patients
(8,442 men; 6313 year-old) underwent PCI after AMI were included
from Korean AMI registry. The ACEF score was calculated as follows:
age/left ventricular ejection fraction þ 1 if serum creatinine >2 mg/dL.
The 1-year MACEs were stratiﬁed according to ACEF score tertiles;
ACEFLOW 1.07 (n¼3,828), 1.07 < ACEFMID  1.44 (n¼3,848), and
ACEFHIGH> 1.44 (n¼3,873). The 1-year MACEs were deﬁned as death,
non-fatal MI, and revascularizations.
RESULTS During the follow-up, rate of MACE was signiﬁcantly higher
in the highest tertile group compared with patients in the lower 2
tertiles (8.5% versus 10.5% versus 24.0%; log-rank p<0.001). In Cox-
proportional hazards model, ACEF score (hazards ratio [HR] 1.60,
p<0.001) in addition to Killip class >1 (HR 1.39, p<0.001), anterior MI
(HR 1.13, p¼0.035), diabetes mellitus (HR 1.27, p<0.001), multivessel
disease (HR 1.51, p<0.001), pre TIMI ﬂow 0 or 1 (HR 1.19, p¼0.07), and
GRACE score (HR 1.01, p<0.001) was an independent predictor of 1-
year MACEs. The respective C-statistics from ACEF score was signiﬁ-
cantly higher compared with those of GRACE score in terms of 1-year
MACEs (0.672 versus 0.651, p¼0.0005) and mortality (0.807 versus
0.777, p¼0.0001). The ACEF score signiﬁcantly improved net reclas-
siﬁcation of patients compared to GRACE score in terms of 1-year
MACEs (0.153, p<0.001) and mortality (0.038, p<0.0001), and also
signiﬁcantly improved integrated discrimination of patients
compared to GRACE score in terms of 1-year MACEs (0.085, p¼0.005)
and mortality (0.028, p<0.001).
CONCLUSIONS The ACEF score improves the discrimination accuracy
of conventional risk model to predict MACEs of patients underwent
PCI after AMI.
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BACKGROUND STEMI patients are at increased risk for recurrent
ischemic events, and guidelines recommend potent P2Y12 inhibitors
for the duration of at least one year after primary PCI. The frequency
and clinical impact of premature prasugrel cessation or a change to
clopidogrel or ticagrelor following primary PCI remains unknown.
METHODS Between September 2009 and June 2012, 1382 patients
with STEMI undergoing primary PCI using newer generation DES and
discharged on dual antiplatelet therapy with prasugrel and aspirin
were enrolled in the framework of the Comfortable trial, SPUM ACS
registry and Bern PCI registry. Prasugrel was prescribed for one year.
Clinical follow-up information was obtained at discharge, 30 days and
one year. Prespeciﬁed categories for prasugrel cessation included
disruption (non-compliance, bleeding, side effects), physician rec-
ommended discontinuation or a change to clopidogrel. All adverse
events and information on prasugrel cessation was collected and
independently adjudicated according to the 3 categories. Using cox
regression models with time-dependent variables, we assessed the
effect of prasugrel cessation on cardiovascular outcomes. The primary
outcome measure was deﬁned as cardiac death, reinfarction, and
stroke. Secondary endpoints included death, cardiac death, reinfarc-
tion and deﬁnite stent thrombosis.
RESULTS A total of 1,382 STEMI patients were included: 1,196 (86.5%)
patients completed DAPT on prasugrel throughout one year; Prasugrel
was disrupted in 48 (3.5%) patients, discontinued in 42 (3%) patients
and switched to another P2Y12 inhibitor in 95 (6.9%) patients. The
adjusted hazard ratio (HR) for MACE after prasugrel disruption tended
to be increased (2.34 (95% CI 0.85-6.38); p¼0.098), while no differ-
ence was observed after premature discontinuation (HR¼ 1.43 (95 CI
0.34-5.91); p¼0.63) or change in type of P2Y12 therapy (HR¼1.20 (95%
CI 0.48-3.01); p¼0.69); in each case compared to the period the pa-
tients were on DAPT with prasugrel. Disruption was associated with
an increased risk of death (6.09, 95% CI 1.72-21.59, p¼0.005), cardiac
mortality (HR¼4.63, 95% CI 1.00-21.54; p¼0.05) and stent thrombosis
(HR¼4.22, 95% CI 1.27-14.05, p¼0.019), while there was a trend to-
wards an increased risk of MI (HR¼2.78, 95% CI 0.86-8.94, p¼0.087).
CONCLUSIONS A high proportion STEMI patients remained on DAPT
with prasugrel throughout one year after primary PCI in routine
clinical practice. Prasugrel disruption is infrequent but associated
with an increased risk for ischemic cardiovascular events compared to
physician guided discontinuation or change to clopidogrel.
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BACKGROUND Several conditions may mimic a true ST Elevation
Myocardial Infarction (STEMI) and lead to false activation of the
Cardiac Catheterization Laboratory (CCL). We investigated the rea-
sons for false STEMI activations at our institution.
METHODS We reviewed the medical records of all patients presenting
to our institution for percutaneous coronary intervention for possible
STEMI from July 2012 to November 2014. A false STEMI activation was
